Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars
The company will not commercialize an insulin glargine copy already tentatively approved by FDA as Lusduna, but says it remains committed to biosimilars in oncology and immunology.
You may also be interested in...
Merck & Co has disclosed more precise details around plans to spin off its more mature products, including biosimilars, into a new publicly traded company.
The FDA Commissioner called on payers to take steps to build the US biosimilar market and discouraged some early contracting schemes, calling them pay-for-delay tactics "dressed in the guise of rebates" in a notable speech at AHIP.
Exclusive contracts for J&J's Remicade have posed challenges for Pfizer's Inflectra in the commercial insurance market, the biosimilar's maker said during its second quarter earnings call.